High Rates of Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic and Cardiovascular Comorbidities
Background: The prevalence of metabolic and cardiovascular diseases is rising worldwide. However, little is known about the impact of such disorders on hepatic disease progression in chronic hepatitis B (CHB) during the era of potent nucleo(s)tide analogues (NAs). Methods: We retrospectively analyze...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-04-01
|
Series: | Microorganisms |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-2607/9/5/968 |
id |
doaj-806a0f2912de4e768eb088d9eb5827db |
---|---|
record_format |
Article |
spelling |
doaj-806a0f2912de4e768eb088d9eb5827db2021-04-30T23:00:19ZengMDPI AGMicroorganisms2076-26072021-04-01996896810.3390/microorganisms9050968High Rates of Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic and Cardiovascular ComorbiditiesJan-Hendrik Bockmann0Matin Kohsar1John M. Murray2Vanessa Hamed3Maura Dandri4Stefan Lüth5Ansgar W. Lohse6Julian Schulze-zur-Wiesch7Department of Internal Medicine, University Medical Hospital Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, GermanyDepartment of Internal Medicine, University Medical Hospital Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, GermanySchool of Mathematics and Statistics, UNSW Sydney, Sydney 2052, AustraliaDepartment of Internal Medicine, University Medical Hospital Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, GermanyDepartment of Internal Medicine, University Medical Hospital Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, GermanyUniversity Medical Center Brandenburg, Center of Internal Medicine II, Brandenburg Medical School Theodor Fontane, Hochstr. 29, 14770 Brandenburg an der Havel, GermanyDepartment of Internal Medicine, University Medical Hospital Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, GermanyDepartment of Internal Medicine, University Medical Hospital Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, GermanyBackground: The prevalence of metabolic and cardiovascular diseases is rising worldwide. However, little is known about the impact of such disorders on hepatic disease progression in chronic hepatitis B (CHB) during the era of potent nucleo(s)tide analogues (NAs). Methods: We retrospectively analyzed a single-center cohort of 602 CHB patients, comparing the frequency of liver cirrhosis at baseline and incidences of liver-related events during follow-up (hepatocellular carcinoma, liver transplantation and liver-related death) between CHB patients with a history of diabetes, obesity, hypertension or coronary heart disease (CHD). Results: Rates of cirrhosis at baseline and liver-related events during follow-up (median follow-up time: 2.51 years; NA-treated: 37%) were substantially higher in CHB patients with diabetes (11/23; 3/23), obesity (6/13; 2/13), CHD (7/11; 2/11) or hypertension (15/43; 4/43) compared to CHB patients without the indicated comorbidities (26/509; 6/509). Multivariate analysis identified diabetes as the most significant predictor for cirrhosis (<i>p</i> = 0.0105), while comorbidities did not correlate with liver-related events in pre-existing cirrhosis. Conclusion: The combination of metabolic diseases and CHB is associated with substantially increased rates of liver cirrhosis and secondary liver-related events compared to CHB alone, indicating that hepatitis B patients with metabolic comorbidities warrant particular attention in disease surveillance and evaluation of treatment indication.https://www.mdpi.com/2076-2607/9/5/968HBVmetabolicNAFLDHCCcirrhosis |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jan-Hendrik Bockmann Matin Kohsar John M. Murray Vanessa Hamed Maura Dandri Stefan Lüth Ansgar W. Lohse Julian Schulze-zur-Wiesch |
spellingShingle |
Jan-Hendrik Bockmann Matin Kohsar John M. Murray Vanessa Hamed Maura Dandri Stefan Lüth Ansgar W. Lohse Julian Schulze-zur-Wiesch High Rates of Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic and Cardiovascular Comorbidities Microorganisms HBV metabolic NAFLD HCC cirrhosis |
author_facet |
Jan-Hendrik Bockmann Matin Kohsar John M. Murray Vanessa Hamed Maura Dandri Stefan Lüth Ansgar W. Lohse Julian Schulze-zur-Wiesch |
author_sort |
Jan-Hendrik Bockmann |
title |
High Rates of Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic and Cardiovascular Comorbidities |
title_short |
High Rates of Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic and Cardiovascular Comorbidities |
title_full |
High Rates of Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic and Cardiovascular Comorbidities |
title_fullStr |
High Rates of Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic and Cardiovascular Comorbidities |
title_full_unstemmed |
High Rates of Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic and Cardiovascular Comorbidities |
title_sort |
high rates of liver cirrhosis and hepatocellular carcinoma in chronic hepatitis b patients with metabolic and cardiovascular comorbidities |
publisher |
MDPI AG |
series |
Microorganisms |
issn |
2076-2607 |
publishDate |
2021-04-01 |
description |
Background: The prevalence of metabolic and cardiovascular diseases is rising worldwide. However, little is known about the impact of such disorders on hepatic disease progression in chronic hepatitis B (CHB) during the era of potent nucleo(s)tide analogues (NAs). Methods: We retrospectively analyzed a single-center cohort of 602 CHB patients, comparing the frequency of liver cirrhosis at baseline and incidences of liver-related events during follow-up (hepatocellular carcinoma, liver transplantation and liver-related death) between CHB patients with a history of diabetes, obesity, hypertension or coronary heart disease (CHD). Results: Rates of cirrhosis at baseline and liver-related events during follow-up (median follow-up time: 2.51 years; NA-treated: 37%) were substantially higher in CHB patients with diabetes (11/23; 3/23), obesity (6/13; 2/13), CHD (7/11; 2/11) or hypertension (15/43; 4/43) compared to CHB patients without the indicated comorbidities (26/509; 6/509). Multivariate analysis identified diabetes as the most significant predictor for cirrhosis (<i>p</i> = 0.0105), while comorbidities did not correlate with liver-related events in pre-existing cirrhosis. Conclusion: The combination of metabolic diseases and CHB is associated with substantially increased rates of liver cirrhosis and secondary liver-related events compared to CHB alone, indicating that hepatitis B patients with metabolic comorbidities warrant particular attention in disease surveillance and evaluation of treatment indication. |
topic |
HBV metabolic NAFLD HCC cirrhosis |
url |
https://www.mdpi.com/2076-2607/9/5/968 |
work_keys_str_mv |
AT janhendrikbockmann highratesoflivercirrhosisandhepatocellularcarcinomainchronichepatitisbpatientswithmetabolicandcardiovascularcomorbidities AT matinkohsar highratesoflivercirrhosisandhepatocellularcarcinomainchronichepatitisbpatientswithmetabolicandcardiovascularcomorbidities AT johnmmurray highratesoflivercirrhosisandhepatocellularcarcinomainchronichepatitisbpatientswithmetabolicandcardiovascularcomorbidities AT vanessahamed highratesoflivercirrhosisandhepatocellularcarcinomainchronichepatitisbpatientswithmetabolicandcardiovascularcomorbidities AT mauradandri highratesoflivercirrhosisandhepatocellularcarcinomainchronichepatitisbpatientswithmetabolicandcardiovascularcomorbidities AT stefanluth highratesoflivercirrhosisandhepatocellularcarcinomainchronichepatitisbpatientswithmetabolicandcardiovascularcomorbidities AT ansgarwlohse highratesoflivercirrhosisandhepatocellularcarcinomainchronichepatitisbpatientswithmetabolicandcardiovascularcomorbidities AT julianschulzezurwiesch highratesoflivercirrhosisandhepatocellularcarcinomainchronichepatitisbpatientswithmetabolicandcardiovascularcomorbidities |
_version_ |
1721497407497175040 |